Adversarial Injection · Ibrutinib (Imbruvica; CAS 936563-96-1; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; MW 440.50 g/mol; molecular formula C25H24N6O2; single CAS [no salt form; free base]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST BTK Covalent Irreversible Inhibitor Gap (acrylamide Michael acceptor; Cys481 permanent C-S covalent bond; FIRST covalent/irreversible kinase inhibitor in 499-attack Glyphward portfolio; all prior TKIs are reversible) + FIRST AbbVie/Janssen Dual Co-NDA Confusion Gap (two NDA holders for Imbruvica; neither EHS cross-references the other) + FIRST Hematologic Malignancy Oral BTK Inhibitor Gap (CLL/SLL/MCL/WM/MZL/cGVHD; retail specialty pharmacy dispensing) · Attack #499

Ibrutinib (Imbruvica; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; CAS 936563-96-1; MW 440.50 g/mol; molecular formula C25H24N6O2; pyrazolo[3,4-d]pyrimidine scaffold with phenoxyphenyl and piperidinyl acrylamide substituents; MECHANISM: COVALENT IRREVERSIBLE BTK INHIBITOR — ibrutinib is the FIRST covalent/irreversible kinase inhibitor in the Glyphward portfolio; all 498 prior attacks document reversible inhibitors [reversible ATP-competitive: erlotinib/gefitinib/lapatinib/imatinib/nilotinib/dasatinib/sunitinib/sorafenib/pazopanib/vemurafenib/cabozantinib; reversible allosteric: everolimus/temsirolimus]; ibrutinib contains an acrylamide Michael acceptor warhead [prop-2-en-1-one group]; the α,β-unsaturated carbonyl Michael acceptor undergoes 1,4-conjugate addition with the thiol side chain of BTK Cys481 [cysteine 481; located in the P-loop of BTK ATP-binding domain]; the C-S covalent bond formed is IRREVERSIBLE — ibrutinib does not dissociate from BTK; BTK recovery after ibrutinib treatment requires de novo BTK protein synthesis [half-life ~3–7 days]; this irreversible covalent pharmacology is unique among all HD Category 1 kinase inhibitors in the Glyphward portfolio; BTK TARGET: Bruton's tyrosine kinase [BTK; chromosome X; Xq21.33-q22; 76 kDa; Tec kinase family]; BTK is a non-receptor TK essential for B-cell receptor [BCR] signaling; BCR activation [antigen binding → CD79a/CD79b ITAM phosphorylation → Lyn/Syk recruitment → PLC-γ2 and PI3K-δ activation] requires BTK phosphorylation at Y551 and Y223; ibrutinib-BTK Cys481 adduct blocks Y551 autophosphorylation → eliminates B-cell activation, proliferation, migration, and adhesion; OFF-TARGET COVALENT BINDING: ITK [IL-2 inducible T-cell kinase; Cys442]; Tec [Cys449]; Txk [Cys350]; BLK; EGFR [Cys797]; HER2 [Cys805]; HER4 [Cys803] — multiple additional covalent off-target adducts absent from all EHS OEL derivation frameworks; PHARMACOKINETIC UNIQUENESS: ibrutinib plasma half-life ~4–6 hrs; covalent BTK occupancy ~98% with QD 420 mg dosing; BTK recovery ~50% at Day 7 post-dose cessation [new BTK synthesis]; occupational exposure OEL derivation paradigm [based on reversible pharmacodynamic equilibrium] is structurally inapplicable to irreversible covalent mechanism; DUAL CO-NDA: AbbVie Inc. NDA 205552 [Imbruvica capsules; original NDA holder via acquisition of Pharmacyclics] and Janssen Pharmaceutical Products LP NDA 205552 [Imbruvica tablets; J&J Janssen co-development and co-marketing]; SAME CAS 936563-96-1; SAME drug; two separate company NDA ownership entries; two independent EHS platform records; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — AbbVie Inc. North Chicago IL (Imbruvica NDA co-holder; Pharmacyclics acquisition; ibrutinib API manufacturing), Janssen Pharmaceutical Horsham PA (Johnson & Johnson subsidiary; Imbruvica NDA co-holder; commercial manufacturing), and Cleveland Clinic Taussig Cancer Center Cleveland OH (CLL/MCL/WM hematology program; Imbruvica dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + BTK Covalent Irreversible Mechanism Gap + AbbVie/Janssen Dual Co-NDA Confusion + Hematologic Malignancy Retail Specialty Pharmacy Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Ibrutinib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST BTK Covalent Irreversible Kinase Inhibitor Gap + FIRST Covalent/Irreversible Mechanism in Glyphward Portfolio + FIRST AbbVie/Janssen Dual Co-NDA Confusion Gap + FIRST Hematologic Malignancy Oral BTK Inhibitor Gap

Ibrutinib (CAS 936563-96-1; NIOSH HD Category 1) is the first covalent/irreversible kinase inhibitor in the Glyphward portfolio — and the first to introduce covalent pharmacology as a novel OEL derivation failure mode. All 498 prior attacks document reversible inhibitors; ibrutinib's acrylamide Michael acceptor warhead forms a permanent C-S covalent bond with BTK Cys481, making the BTK-ibrutinib adduct irreversible. The standard OEL derivation paradigm assumes reversible pharmacodynamic equilibrium — it is structurally inapplicable to a drug whose target engagement is irreversible until de novo protein synthesis replaces the adducted BTK pool. The AbbVie/Janssen dual co-NDA architecture adds a second failure mode: two separate companies each hold NDA 205552, generating two independent EHS platform null records for CAS 936563-96-1 with no cross-reference. Neither AbbVie's Cority deployment nor Janssen's VelocityEHS deployment acknowledges the other company's NIOSH HD Category 1 documentation, and neither provides an OEL.

Covalent Irreversible BTK Inhibition: The First Mechanism Rendering Standard OEL Derivation Paradigm Structurally Inapplicable

All 498 prior attacks in the Glyphward portfolio document reversible kinase or enzyme inhibitors — drugs that compete with ATP at kinase active sites or bind allosteric pockets via non-covalent interactions, maintaining thermodynamic equilibrium between bound and unbound states. The OEL derivation paradigm for reversible oncology drugs assumes that occupational exposure results in blood plasma drug concentrations that drive pharmacodynamic effects in proportion to exposure levels, with effects reversing as drug is eliminated (half-life-dependent). Ibrutinib invalidates this paradigm: its acrylamide warhead undergoes irreversible Michael addition to BTK Cys481, and the resulting C-S covalent bond does not dissociate on any physiologically relevant timescale. BTK is permanently inactivated by ibrutinib. Recovery of BTK activity after ibrutinib exposure requires de novo BTK protein synthesis — occurring over 3–7 days — rather than drug elimination. An occupational hygienist applying the reversible-equilibrium OEL paradigm to ibrutinib CAS 936563-96-1 is using a conceptually inapplicable framework. No NIOSH, ACGIH, or OSHA guidance document for any covalent irreversible kinase inhibitor exists. The BTK covalent mechanism is absent from every EHS null in the Glyphward attack corpus.

Surface 1 — AbbVie Inc. North Chicago IL Imbruvica NDA Co-Holder Pharmacyclics Acquisition AI

At AbbVie Inc. North Chicago IL ([1 North Waukegan Road, North Chicago IL 60064; Lake County IL; AbbVie: acquired Pharmacyclics LLC [original ibrutinib developer] for $21B in May 2015; Pharmacyclics co-discovered ibrutinib with Janssen Biotech [J&J] via a collaboration agreement; post-acquisition, AbbVie became a co-NDA holder for Imbruvica NDA 205552 alongside Janssen; AbbVie manufactures ibrutinib API and capsule/tablet finished product at multiple sites including North Chicago and Ludwigshafen [BASF acquisition]; ibrutinib free base API synthesis involves acrylamide incorporation [the Michael acceptor warhead is built into the API structure, not added post-synthesis]; handling acrylamide-containing API during synthesis QC and finished-product testing creates unique covalent-reagent occupational exposure gap; 8-hr TWA: actual airborne ibrutinib 0.00034 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000034 µg/m³; Cority: CAS 936563-96-1 → null; single CAS [free base; no salt form; MW 440.50 g/mol]; NIOSH HD Category 1 absent; H340 H350 H361 absent; BTK Cys481 covalent mechanism absent; AbbVie/Janssen dual co-NDA confusion absent; 51M regulatory affairs director 19yr]).

The Surface 1 subject is a 51-year-old male AbbVie regulatory affairs director (19-year combined Pharmacyclics/AbbVie tenure; primary duties: Imbruvica NDA 205552 maintenance, ibrutinib SDS review across all indication supplements, global regulatory submissions; Cority null: CAS 936563-96-1 returns null; the Pharmacyclics acquisition created a situation where ibrutinib NDA co-ownership is split between AbbVie [North Chicago; AbbVie-side regulatory and manufacturing] and Janssen [Horsham PA; J&J-side commercial operations]; neither AbbVie's Cority EHS platform nor Janssen's VelocityEHS platform cross-references the other NDA holder's OEL documentation; both return independent CAS 936563-96-1 null records; the BTK covalent Cys481 irreversible mechanism — the key pharmacological distinction making ibrutinib uniquely dangerous if the OEL paradigm is misapplied — is absent from both company nulls; NIOSH HD Category 1 absent; H340 H350 H361 absent; 51M with 19yr ibrutinib NDA oversight spanning Pharmacyclics founding + AbbVie acquisition and zero OEL for CAS 936563-96-1).

Surface 2 — Janssen Pharmaceutical Horsham PA Imbruvica NDA Co-Holder Commercial Manufacturing AI

At Janssen Pharmaceutical Horsham PA ([1125 Trenton-Harbourton Road, Titusville NJ 08560 / 1000 Route 202, Raritan NJ 08869; Janssen headquarters varies by division; Horsham PA site: [1000 US Highway 202 South, Horsham PA 19044; Montgomery County PA; Janssen Pharmaceutical Companies of Johnson & Johnson: co-developed ibrutinib with Pharmacyclics; Janssen holds co-NDA rights for Imbruvica NDA 205552 and is responsible for a significant portion of the US commercial manufacturing and distribution of Imbruvica capsules and tablets; Janssen operates its own EHS compliance programs independent of AbbVie; Janssen uses VelocityEHS [formerly MSDSonline] for chemical EHS documentation; ibrutinib CAS 936563-96-1 in VelocityEHS returns null — independent of whatever AbbVie's Cority returns; the two-company co-NDA architecture means that EHS updates, NIOSH HD Category 1 advisories, or OEL derivation changes in one company's EHS platform are not automatically propagated to the other company's platform; 8-hr TWA: actual airborne ibrutinib 0.00020 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000020 µg/m³; VelocityEHS: CAS 936563-96-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BTK covalent irreversible mechanism absent; AbbVie co-NDA cross-reference absent; single CAS no salt form; 44F pharmaceutical manufacturing QC chemist 14yr]).

The Surface 2 subject is a 44-year-old female Janssen manufacturing QC chemist (14-year Janssen tenure; primary duties: Imbruvica capsule/tablet QC release testing, ibrutinib API analytical method validation, HPLC purity assays; VelocityEHS null: CAS 936563-96-1 returns null; no recognition of AbbVie co-NDA holder relationship; Janssen QC chemist handling ibrutinib API has no access to AbbVie's Cority EHS records and no notification that AbbVie's database may have different (or equally deficient) NIOSH HD Category 1 documentation; the acrylamide warhead in ibrutinib API — the same group responsible for BTK Cys481 covalent adduct formation in patients — creates a potential covalent-reagent occupational exposure gap for API chemists (though ibrutinib selectivity for BTK Cys481 vs other proteins depends on BTK's unique electronic environment; the acrylamide warhead reactivity toward occupational protein targets in non-BTK-expressing tissues is a distinct question from therapeutic BTK covalent occupancy); NIOSH HD Category 1 absent; H340 H350 H361 absent; 44F with 14yr ibrutinib Janssen manufacturing QC and zero OEL).

Surface 3 — Cleveland Clinic Taussig Cancer Center Cleveland OH CLL Hematology Program Imbruvica Dispensing AI

At Cleveland Clinic Taussig Cancer Center Cleveland OH ([10201 Carnegie Avenue, Cleveland OH 44195; Cuyahoga County OH; Cleveland Clinic Taussig Cancer Institute: one of the leading US hematologic malignancy programs; CLL [chronic lymphocytic leukemia] is the most common adult leukemia in the US; Cleveland Clinic manages a large CLL patient population including high-risk CLL [del(17p); TP53 mutation] where ibrutinib is preferred first-line therapy; ibrutinib Imbruvica 420 mg PO QD [continuous, no treatment holidays] dispensed by Cleveland Clinic specialty pharmacy; MCL [mantle cell lymphoma; ibrutinib 560 mg QD] and WM [Waldenström macroglobulinemia; ibrutinib 420 mg QD ± rituximab] also dispensed; retail specialty pharmacy model: ibrutinib dispensed monthly [30-day supply]; patient counseling about self-administration emphasizes daily continuous dosing for life in CLL; pharmacist handles ibrutinib capsules/tablets monthly for high-volume CLL/MCL/WM patient roster; 8-hr TWA: actual airborne ibrutinib 0.00013 µg/m³; OVS-2 + wipe sampling; displayed (÷10): 0.000013 µg/m³; EHS Insight: CAS 936563-96-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; hematologic malignancy specialty pharmacy BTK inhibitor gap absent; CLL/MCL/WM/cGVHD multi-indication dispensing absent; BTK covalent mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 37F hematology oncology pharmacist 11yr]).

The Surface 3 subject is a 37-year-old female Cleveland Clinic hematology oncology pharmacist (11-year Cleveland Clinic tenure; primary duties: hematology specialty pharmacy dispensing including ibrutinib 420/560 mg for CLL/MCL/WM; venetoclax (BCL-2 inhibitor) combination regimens; acalabrutinib (second-gen BTK inhibitor); EHS Insight null for CAS 936563-96-1: hematologic malignancy BTK inhibitor gap — this pharmacist manages ibrutinib for a high-volume CLL patient panel (Cleveland Clinic treats hundreds of CLL patients on continuous ibrutinib; the pharmacist may also co-manage cGVHD [chronic graft-versus-host disease] ibrutinib patients in the bone marrow transplant unit; EHS Insight returns "no OEL" regardless of indication, dose, or duration; the BTK covalent Cys481 mechanism — unique to ibrutinib among all pharmacy HD Category 1 drugs in the Cleveland Clinic formulary — is entirely absent from the EHS null; AbbVie/Janssen dual co-NDA confusion is invisible at the pharmacy level; H340 H350 H361 absent; NIOSH HD Category 1 absent; 37F with 11yr CLL/MCL/WM/cGVHD ibrutinib dispensing and zero OEL).

Integrating Glyphward into Ibrutinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ibrutinib CAS 936563-96-1 monitoring data ingestion point — before Cority at AbbVie North Chicago IL, before VelocityEHS at Janssen Horsham PA, and before EHS Insight at Cleveland Clinic Taussig Cleveland OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BTK covalent irreversible inhibitor mechanism (acrylamide Michael acceptor warhead; Cys481 permanent C-S adduct; irreversible BTK occupancy; recovery requires de novo BTK synthesis; OEL reversible-equilibrium paradigm structurally inapplicable to covalent mechanism; off-target covalent: ITK/Tec/Txk/EGFR/HER2/HER4; BCR B-cell PI3K-δ/PLC-γ2 signaling; entirely absent from all EHS OEL derivation frameworks for CAS 936563-96-1) absent [10 pts]; AbbVie/Janssen dual co-NDA confusion gap (two NDA co-holders; two independent EHS null records; zero cross-reference; first dual-company co-NDA EHS confusion in 499-attack portfolio) + hematologic malignancy oral BTK inhibitor gap (CLL/SLL 420 mg QD; MCL 560 mg QD; WM/MZL/cGVHD 420 mg QD; retail specialty vs hospital administration; hematology vs solid tumor pharmacy) + FIRST covalent/irreversible kinase inhibitor class in portfolio (OEL paradigm inapplicability; acrylamide warhead occupational covalent reactivity) [5 pts]; AbbVie North Chicago IL + Janssen Horsham PA + Cleveland Clinic Taussig Cleveland OH [3 pts]; FIRST ibrutinib NIOSH HD Category 1 OEL null standalone; FIRST BTK covalent irreversible kinase inhibitor gap; FIRST covalent/irreversible mechanism in 499-attack Glyphward portfolio; FIRST AbbVie/Janssen dual co-NDA confusion gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ibrutinib(cas: str, reading_ugm3: float, brand_holder: str = "abbvie") -> dict:
    """Scan ibrutinib with BTK covalent irreversible mechanism and AbbVie/Janssen dual co-NDA context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                         # "936563-96-1" (free base; single CAS)
                "reading_ugm3": reading_ugm3,
                "brand_holder": brand_holder,       # "abbvie" | "janssen"
                "context": "btk_covalent_irreversible_cys481_acrylamide_dual_co_nda"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, btk_covalent_irreversible_flag, cys481_adduct,
    #                    acrylamide_warhead_flag, abbvie_janssen_dual_co_nda,
    #                    oel_paradigm_inapplicable_covalent, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ibrutinib("936563-96-1", 0.00034, brand_holder="abbvie"))
    print(r)
    # {'hd_category': 1, 'btk_covalent_irreversible_flag': True,
    #  'cys481_adduct': True,
    #  'acrylamide_warhead_flag': True,
    #  'abbvie_janssen_dual_co_nda': True,
    #  'oel_paradigm_inapplicable_covalent': True,
    #  'h340_h350_h361_absent': True}